Crystallization Microplates
Hampton Research 50% W/V POLY(ACRYLIC AC 200ML
HR2-773/50% w/v Poly(acrylic acid sodium salt) 5,100 - 200 ml. Please note items from this supplier are non-returnable.
Cayman Chemical AvRmectIn B1a monsaccharID 1mg
A synthetic glucocorticoid with anti-inflammatory properties inhibits edema by 55 in a RPA test in rabbit when administered topically (0.1 w/w) inhibits edema by 70.1 and 88.0 in croton oil-induced and PCA tests respectively in rat (topical 0.1 w/w) in vivo application (0.1 w/w) to the abraded surface of cecum in rats inhibits leukocyte adhesion (43.3 incidence versus 100 for controls) and lowers the total number of intraperitoneal leukocytes from 270 million to 121 million 3 days post surgery acts as an agonist at the Smo receptor (EC50 1100 nM)
Cayman Chemical 2-AvermectIn B1a 1mg
An inhibitor of P-gp selectively reverses multidrug resistance mediated by P-gp over MRP1- and BCRP-mediated multidrug resistance resensitizes SKOV3TR and OVCAR-8TR cells to paclitaxel reverses P-gp efflux increasing the intracellular accumulation of P-gp substrates in multidrug resistant SKOV3TR and OVCAR-8TR cells prevents paclitaxel-induced overexpression of MDR1 and P-gp protein level increases in OVCAR-8 cells prevents the development of paclitaxel-induced multidrug resistance in a SKOV3 mouse xenograft model at 50 mg/kg per day in combination with paclitaxel
Cayman Chemical AvRmectIn B1a monsaccharID 5mg
A synthetic glucocorticoid with anti-inflammatory properties inhibits edema by 55 in a RPA test in rabbit when administered topically (0.1 w/w) inhibits edema by 70.1 and 88.0 in croton oil-induced and PCA tests respectively in rat (topical 0.1 w/w) in vivo application (0.1 w/w) to the abraded surface of cecum in rats inhibits leukocyte adhesion (43.3 incidence versus 100 for controls) and lowers the total number of intraperitoneal leukocytes from 270 million to 121 million 3 days post surgery acts as an agonist at the Smo receptor (EC50 1100 nM)
Cayman Chemical EmamectIn B1a 5mg
An orally bioavailable and ATP-competitive multi-AGC kinase inhibitor inhibits Akt1 2 and 3 (IC50s 38 402 and 50 nM respectively) inhibits p70S6K PKA and ROCK1 and ROCK2 (IC50s 3-8 nM) antiproliferative against cancer cell lines with genetic mutations in PI3K-Akt-mTOR or RAS-RAF pathways (GI50s 1.54-3.77 M) inhibits growth of MES-SA uterine sarcoma and BT474 breast cancer xenografts in mice (50 mg/kg p.o.) inhibits ROCK-dependent phosphorylation of MLC2 over a 24-hour period in 4599 mouse melanoma cells (EC50 0.1 M) reduces motility of 4699 melanoma cells in murine xenograft model
Cayman Chemical EprInomectIn B1a 1mg
A potent inhibitor of Cdc7 (IC50 3 4 nM) 60 10 and 300-fold selective for Cdc7 over CK2 PIM1 and a panel of over 100 protein kinases respectively inhibits the growth of MDA-MB-231T and COLO 205 cells (IC50s 118 and 140 nM respectively) inhibits Cdc7-specific phosphorylation of MCM2 and induces cell cycle accumulation in the S and G2 phases in MDA-MB-231T and COLO 205 cells inhibits MCM2 phosphorylation (ED50 3 mg/kg) and reduces tumor growth in a COLO 205 mouse xenograft model at 10 30 and 100 mg/kg
Molecular Dimensions MemTrans™
A unique screen designed for transporter proteins. MemTrans uniquely targets transporter proteins. Includes the most common transporter protein crystallization conditions to maximize your chances of success.
Molecular Dimensions The Ligand-Friendly Screen
The Ligand-Friendly Screen (LFS)1 has been one of the two primary coarse screens of the Structural Genomics Consortium (SGC) in Oxford since 2004; at last count, it had produced 190 novel structures over 10 years.
RIGAKU REAGENTS Block, JCSG Core Suite 2, 96 conditions, 1.7mL volumes
The Joint Center for Structural Genomics formatted the JCSG Core Suite screens as a result of analyzing over 500,000 high-throughput crystallization experiments, performed at the JCSG. The 384 crystallization formulations were selected based on the highest hit rates in initial screening.